Novo Nordisk’s GLP-1 Franchise Buoyed By SUSTAIN FORTE data

Showed Superior Diabetes Risk-Benefit From Higher Ozempic Dose

 
• By Sten Stovall
SUSTAIN FORTE Compared Investigational 2.0mg dose of semaglutide to 1.0mg • Source: Alamy

More from Clinical Trials

More from R&D